CLINICAL USE


Anti-epileptic agent Neuropathic pain Generalised anxiety disorder

DOSE IN NORMAL RENAL FUNCTION

150–600 mg daily in 2 or 3 divided doses

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :159.2
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0
  • %Excreted unchanged in urine &nbsp &nbsp : 92–99

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.56

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :5–6.5/ Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

    30–60 Initial dose 75 mg daily and titrate according to tolerability and response15–30 Initial dose 25–50 mg daily and titrate according to tolerability and response<15 Initial dose 25 mg daily and titrate according to tolerability and response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR<15 mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR<15 mL/min
  • HDF/high flux &nbsp :Dialysed. Dose as in GFR<15 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR=15–30 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Oral bioavailability >90% 50% of dose is removed after a 4 hour haemodialysis sessionUse with caution in people with severe congestive heart failure. May cause reversible deterioration in renal function.
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt